Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models

13-01-2021

Leadartis reaches a major milestone with the demonstration of absence of toxicity of its EGFR-targeted 4-1BB-agonistic bispecific Trimerbody which does not Induce Hepatotoxicity in transgenic mice with liver expression of human EGFR (https://www.frontiersin.org/articles/10.3389/fimmu.2020.614363/full).

Leadartis closes the investment round in 14 days with an overfunding of 25%

28-09-2020

We are pleased to inform you that the investment round has been successfully closed, raising a total of € 1,250,000 euros, equivalent to 125% of the published goal of 1,000,000 euros. https://capitalcell.es/campaign/leadartis/. We will provide you with additional details as we complete the formalities.

Thank you very much for your participation.

Juan J. Perez Villar, Leadartis CEO

Fund Raising Update: Round completed

21-09-2020

In only ten days Leadartis has completed 100% of its fund-raising needs.

We thank you all for your support! We will allow a small overfunding amount, act quickly if you don´t want to miss out!! Visit the following link should you are still interested in participating. https://capitalcell.es/campaign/leadartis/

Regards, Juan J. Perez Villar, Leadartis CEO

Leadartis presenting at the AseBio Investor Day 2020

17-09-2020

Leadartis will be presenting its business proposal at the AseBio Investor Day (https://asebioevents.com/investorday/presenting-companies/) to be held on September 28-October 1st. AseBio Investor Day is the leading event allowing Spanish innovative biotechnology projects to be presented to an audience of leading international investors and pharmaceutical & industrial companies. The event is organized by AseBio, the Spanish Bioindustry Association.

LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS

11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its own technology (Trimerbody®), opens a financing round of € 1M through the investment platform specialized in biomedicine, Capital Cell. The goal is to continue its research for its first third generation immuno-oncological agent against advanced cancers of the lung, breast and colon. Specifically, the forecast is to finance Phase I studies of its bispecific Trimerbody in patients with advanced or resistant cancers without a therapeutic option.

Trimerbody based therapies for COVID-19: targeting SARS-CoV-2 viral entry mechanism by next-gen trimeric Spikebodies

22-04-2020

The novel coronavirus SARS-CoV-2 has recently emerged as a human pathogen in China, causing fever, severe respiratory illness, and pneumonia a disease recently named coronavirus disease 19 (COVID-19).

LeadArtis to present at the final Chemostart pitching initiative in recognition of its highly innovative R&D activity

31-01-2019
The Chemostart initiative (sponsored by the Chemo company) launched in 2018 as a call for innovative projects focused on adding value to biomedical research. The effort wants to contribute to the discovery of drugs for diseases unmet needs, supporting the best biomedical science. Consequently, the Chemostart initiative (http://www.insudpharma.com/es/chemostart#colaboremos) is meant to promoting the best innovative projects.

Leadartis discloses the project: ATTACK-Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes

11-12-2018

LeadArtis is pleased to announce its participation as coordinator of the ATTACK project (Cancer immunotherapy by bispecific antibodies that recruit T lymphocytes) funded Spanish Ministry of Science, Innovation and Universities (MICINN) under the RETOS 2017 Collaboration program. ATTACK counts with collaborators such as the internationally regarded: Fundación para la Investigación Biomédica del Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid and Centro Nacional de Investigaciones Oncológicas (CNIO).

Syndicate content

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...